Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Up 9.51%
As of Tuesday, November 03, Xilio Therapeutics, Inc.’s XLO share price has surged by 9.51%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Down 9.27%
As of Friday, October 30, Xilio Therapeutics, Inc.’s XLO share price has dipped by 9.27%, which has investors questioning if this is right time to buy.Michael Rose
Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Up 5.60%
As of Thursday, August 06, Xilio Therapeutics, Inc.’s XLO share price has surged by 5.60%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Up 5.42%
As of Thursday, July 23, Xilio Therapeutics, Inc.’s XLO share price has surged by 5.42%, which has investors questioning if this is right time to sell.Michael Rose
Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Down 31.64%
As of Monday, June 02, Xilio Therapeutics, Inc.’s XLO share price has dipped by 31.64%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | XLO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $55.9 | $214.3 | 18% |
|
| Shares Out (Mil) | 6.6 | 53.9 | 17% |
|
| Institutional Ownership | 76.3% | 92.9% | 46% |
|
| Float (Mil) | 3.4 | 41.4 | 9% |
|
| Beta | -0.12 | 0.96 | 4% |
|
| Avg Daily Volume (000s) | 17 | 506 | 20% |
|
| Price Change (52-week) |
(24.3%) | 43.9% | 33% |
|
| Growth | XLO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | 8.7% | (10.1%) | 53% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.1% | (15.7%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | XLO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $64 | $37 | 22% |
|
| Net Income (TTM) (Mil) | ($22) | ($44) | 23% |
|
| EPS (TTM) | ($3.317) | ($1.500) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($61) | ($34) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $15 | $1 | 60% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 24% |
|
| Enterprise Value (Q1) (Mil) | ($70) | $172 | 1% |
|
| Valuation | XLO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.77 | 2.00 | 18% |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | XLO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 83.2% | 67.3% | 90% |
|
| Net Margin | (34.1%) | (63.5%) | 14% |
|
| ROA | (15.2%) | (47.5%) | 22% |
|
| ROE | (55.0%) | (53.3%) | 14% |
|
| Liabilities to Assets | 53.2% | 29.6% | 46% |
|
| F-Score | 4 | 2 | 33% |
|
Xilio Therapeutics, Inc. did not pass any screens on 11/5/2026.
